EquityPandit’s Outlook for Lupin for the week (April 03, 2017 – April 07, 2017) : LUPIN: Lupin closed the week on negative note losing around 2.90%....
Lupin has got the US health regulator’s approval for marketing a generic version of Novartis’ inhalation product Tobi that is used in treating cystic fibrosis...